IP Library › Granted Patent US 10,226,503
Granted Patent B2
US 10,226,503 · App. 15/440,469 · Granted Mar 12, 2019

Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof

Inventor: Yu-Fang Ling (Taipei, TW)
Assignee: CALIWAY BIOPHARMACEUTICALS CO., LTD.
A61K36/9066A61K9/0014A61K9/0019A61K31/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,503
App. No.
15/440,469
Granted
Mar 12, 2019
Kind
B2
Abstract

Disclosed in the present invention is the composition for reducing local fat and body weight, and pharmaceuticals and use thereof. The composition contains resveratrol and curcumin extract at a weight ration from 1:30 to 10:1. The composition and pharmaceuticals thereof of the invention can inhibit the growth of fat cells, cause planned apoptosis of fat cells, achieve the effects of reducing fat cells, and reducing local fat deposition and body weight without causing inflammations or necrosis of surrounding cells or tissues and inflammations or pain reactions of surrounding tissues, thereby avoiding the problems of tissue damage and inflammatory pains caused by liposuction or low invasion fat-dissolving apparatus used in the prior art and the problems such as surrounding tissue inflammations and necrosis infections triggered by cell disruption and necrosis caused by components of a fat-dissolving injection, phosphatidylcholine or sodium deoxycholate.

Claims (24)

1. A method for reducing localized fat at a local site of a subject, comprising:

administering at the local site of the subject a therapeutically effective amount of a pharmaceutical composition comprising resveratrol, and curcumin;

wherein the weight ratio of resveratrol to curcumin ranges from 1:30 to 9:1.

2. The method as claimed in claim 1 , wherein the pharmaceutical composition further comprises a non-ionic surfactant, and the non-ionic surfactant is 2-hydroxyethyl 12-hydroxyoctadecanoate or a polyoxyethylene castor oil derivative.

3. The method as claimed in claim 2 , wherein the polyoxyethylene castor oil derivative is PEG-35 castor oil.

4. The method as claimed in claim 1 , wherein the subject is an animal or a human.

5. The method as claimed in claim 1 , wherein the local site is a localized fat site.

6. The method as claimed in claim 5 , wherein the localized fat site is a face, jaw, arm, waist, abdomen, or thighs.

7. The method as claimed in claim 1 , wherein the pharmaceutical composition is administered by injection, subcutaneous implantation, implantable infusion, ointment, or patch.

8. The method as claimed in claim 7 , wherein the injection is subcutaneous injection.

9. The method as claimed in claim 8 , the subcutaneous injection is injected to subcutaneous fat layer.

10. The method as claimed in claim 7 , wherein the effective amount of the pharmaceutical composition is from 0.4 mg/kg BW to 100 mg/kg BW.

11. The method as claimed in claim 10 , wherein the effective amount of the pharmaceutical composition is from 1 mg/kg BW to 60 mg/kg BW.

12. A method for reducing weight of a subject, comprising:

administering at a local site of the subject a therapeutically effective amount of a pharmaceutical composition comprising resveratrol, and curcumin;

wherein the weight ratio of resveratrol to curcumin ranges from 1:30 to 9:1.

13. The method as claimed in claim 12 , wherein the pharmaceutical composition further comprises a non-ionic surfactant, and the non-ionic surfactant is a polyoxyethylene castor oil derivative.

14. The method as claimed in claim 12 , wherein the local site is a localized fat site.

15. The method as claimed in claim 14 , wherein the localized fat site is a face, jaw, arm, waist, abdomen, or thighs.

16. The method as claimed in claim 15 , wherein the pharmaceutical composition is administered via subcutaneous injection.

17. The method as claimed in claim 16 , the subcutaneous injection is injected to subcutaneous fat layer.

18. The method as claimed in claim 15 , wherein the effective amount of the pharmaceutical composition is from 0.4 mg/kg BW to 100 mg/kg BW.

19. The method as claimed in claim 18 , wherein the effective amount of the pharmaceutical composition is from 1 mg/kg BW to 60 mg/kg BW.

20. The method as claimed in claim 13 , wherein the polyoxyethylene castor oil derivative is PEG-35 castor oil.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2017
From: LING, YU-FANG
To: CALIWAY BIOPHARMACEUTICALS CO., LTD.
Reel/Frame 041358/0554 →
Continuity (4)
Continuation In Part 14914971
Provisional Application 62299702 · Feb 25, 2016
Provisional Application 62042864 · Aug 28, 2014
Related Publication 20170157195A1 · Jun 8, 2017